Patents by Inventor James Francis Callahan

James Francis Callahan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dual Pharmacophores - PDE4-Muscarinic Antagonistics
    Publication number: 20090203677
    Abstract: The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.
    Type: Application
    Filed: February 5, 2009
    Publication date: August 13, 2009
    Applicant: Glaxo Group Limited
    Inventors: James Francis Callahan, Guoliang Lin, Zehong Wan, Hongxing Yan
  • Dual Pharmacophores - PDE4-Muscarinic Antagonistics
    Publication number: 20090197871
    Abstract: The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.
    Type: Application
    Filed: February 5, 2009
    Publication date: August 6, 2009
    Applicant: Glaxo Group Limited
    Inventors: James Francis Callahan, Guoliang Lin, Zehong Wan, Hongxing Yan
  • Calcilytic Compounds
    Publication number: 20090163589
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Application
    Filed: February 26, 2009
    Publication date: June 25, 2009
    Inventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
  • Compounds
    Patent number: 7550480
    Abstract: Novel substituted 1,5,7-trisubstituted-1,8-napthyridin-2(1H)-one compounds; 1,5,7 trisubstituted-1,6-napthyridine-2-(1H)-one compounds and 1,5,7-trisubstituted quinoline-2(1H)-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: June 23, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Jeffrey Charles Boehm, James Francis Callahan, Ralph F. Hall, Xichen Lin, Katherine Louise Widdowson
  • Calcilytic compounds
    Patent number: 7514473
    Abstract: Novel Calcilytic compounds and methods of using them are provided.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: April 7, 2009
    Assignee: SmithKline Beecham, Corp.
    Inventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
  • Novel Compounds
    Publication number: 20090069318
    Abstract: Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.
    Type: Application
    Filed: March 24, 2006
    Publication date: March 12, 2009
    Inventors: James Francis Callahan, Jeffrey C. Boehm, Anthony William James Cooper, Stefano Livia, Neysa Nevins, Zehong Wan, Beth A. Norton, Xichen Lin
  • Chemical Compounds
    Publication number: 20080262040
    Abstract: The invention is directed to novel indazole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I): where R1 and R2 are as defined below. These compounds are useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK?) activity, in particular in the treatment and prevention of disorders mediated by IKK2 mechanisms including inflammatory and tissue repair disorders. Such disorders include rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease).
    Type: Application
    Filed: October 20, 2006
    Publication date: October 23, 2008
    Inventors: James Francis Callahan, Jeffrey K. Kerns, Xichen Lin
  • Calcilytic compounds
    Patent number: 7109238
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Grant
    Filed: January 21, 2004
    Date of Patent: September 19, 2006
    Assignees: Smith Kline Beecham Corporation, NPS Pharmaceuticals, Inc.
    Inventors: Maria Amparo Lago, James Francis Callahan, Pradip Kumar Bhatnagar, Eric G. Del Mar, William M. Bryan, Joelle L. Burgess
  • Vitronectin receptor antagonists
    Patent number: 6825188
    Abstract: Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: November 30, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: James Francis Callahan, Russell Donovan Cousins, Richard McCulloch Keenan, Chet Kwon, William Henry Miller, Irene Nijole Uzinskas
  • Calcilytic compounds
    Publication number: 20040192741
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Application
    Filed: January 21, 2004
    Publication date: September 30, 2004
    Applicant: SmithKline Beecham Corporation & NPS Pharmaceuticals
    Inventors: Maria Amparo Lago, James Francis Callahan, Pradip Kumar Bhatnagar, Eric G. Del Mar, William M. Bryan, Joelle L. Burgess
  • Vitronectin receptor antagonists
    Publication number: 20040082559
    Abstract: Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.
    Type: Application
    Filed: October 22, 2003
    Publication date: April 29, 2004
    Applicant: SmithKline Beecham Corporation
    Inventors: James Francis Callahan, Russell Donovan Cousins, Richard McCulloch Keenan, Chet Kwon, William Henry Miller, Irene Nijole Uzinskas
  • Vitronectin receptor antagonists
    Publication number: 20030125317
    Abstract: Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.
    Type: Application
    Filed: December 16, 2002
    Publication date: July 3, 2003
    Applicant: SmithKline Beecham Corporation
    Inventors: James Francis Callahan, Russell Donovan Cousins, Richard McCulloch Keenan, Chet Kwon, William Henry Miller, Irene Nijole Uzinskas
  • Calcilytic compounds
    Publication number: 20030018203
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Application
    Filed: July 17, 2002
    Publication date: January 23, 2003
    Inventors: Maria Amparo Largo, James Francis Callahan, Pradip Kumar Bhatnagar, Eric G. Del Mar, William M. Bryan, Joelle L. Burgess
  • Bicyclic fibrinogen antagonists
    Patent number: 6403578
    Abstract: This invention relates to compounds of the formulae: wherein A1 is O, S, N—R1 or CHR1; A4 is N—R4 or CHR4; R2 is a sidechain containing an acid or ester group; R1, R4 and R5 are substituents such as H, alkyl and aryl alkyl, and R6 is a sidechain containing a nitrogen group; and pharmaceutically acceptable salts thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.
    Type: Grant
    Filed: August 4, 1995
    Date of Patent: June 11, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: William Edward Bondinell, James Francis Callahan, William Francis Huffman, Richard McCulloch Keenan, Thomas Wen-Fu Ku, Kenneth Allen Newlander, James Martin Samanen, Irene Nijole Uzinskas
  • Calcilytic compounds
    Patent number: 6395919
    Abstract: Novel calcilytic compounds, pharmaceuticals compositions cotaining said compounds and their use as calcium receptor antagonists.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: May 28, 2002
    Assignees: SmithKline Beecham Corporation, NPS Pharmaceuticals
    Inventors: Pradip Kumar Bhatnagar, Joelle Lorraine Burgess, James Francis Callahan, Raul Rolando Calvo, Eric G. Del Mar, Maria Amparo Lago, Thomas The Nguyen
  • Calcilytic compounds and method of use
    Publication number: 20020052509
    Abstract: Calcilytic compounds and compositions and their use in treating abnormal bone or mineral homeostasis.
    Type: Application
    Filed: December 4, 2001
    Publication date: May 2, 2002
    Applicant: SmithKline Beecham Corporation
    Inventors: Pradip Kumar Bhatnagar, James Francis Callahan, Eric G. Del Mar, Maria Amparo Lago
  • Calcilytic compounds
    Patent number: 6294531
    Abstract: Novel arylalkylamino compounds exhibiting calcilytic properties are provided.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: September 25, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Robert M. Barmore, Pradip Kumar Bhatnagar, William M. Bryan, Joelle Lorraine Burgess, James Francis Callahan, Raul Rolando Calvo, Eric G. Del Mar, Maria Amparo Lago, Thomas The Nguyen, Derek Sheehan, Robert Lawrence Smith, Linda Sue Southall, Bradford C. Van Wagenen
  • Hemoregulatory compounds
    Patent number: 6191146
    Abstract: The present invention relates to novel compounds which have hemoregulatory activities and can be used to stimulate hematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: February 20, 2001
    Assignees: SmithKline Beecham Corporation, Nycomed Austria GmbH
    Inventors: Pradip Kumar Bhatnagar, Dirk Andries Heerding, James Francis Callahan, Michael Hartmann, Johann Hiebl, Peter Kremminger, Franz Rovenszky
  • Bicyclic fibrinogen antagonists
    Patent number: 6127359
    Abstract: Compounds of the formula: ##STR1## wherein A.sup.1 to A.sup.5 form a seven-membered ring containing one optionally substituted nitrogen atom and one heteroatom selected from oxygen and nitrogen;D.sup.1 to D.sup.4 form a substituted six membered ring, optionally containing up to two nitrogen atoms;R is preferably at least one acid containing substituent;R* is is one or more groups chosen from H, Q-C.sub.1-6 alkyl, Q-C.sub.1-6 oxoalkyl, Q-C.sub.2-6 alkenyl, Q-C.sub.3-4 oxoalkenyl, Q-C.sub.3-4 oxoalkynyl, Q-C.sub.2-4 alkynyl, C.sub.3-6 cycloalkyl, Ar or Het;Q is H, C.sub.3-6 cycloalkyl, Het or Ar;R.sup.6 is preferably a basic nitrogen containing substituent;are inhibitors of platelet aggregation.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: October 3, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: William Edward Bondinell, James Francis Callahan, William Francis Huffman, Richard McCulloch Keenan, Thomas Wen-Fu Ku, Kenneth Allen Newlander
  • Bicyclic fibrinogen antagonists
    Patent number: 6117910
    Abstract: This invention relates to compounds of the formula: ##STR1## which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: September 12, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: James Francis Callahan, Richard McCulloch Keenan, Chet Kwon, James Martin Samanen